Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Intangibles (2018 - 2025)

Autolus Therapeutics (AUTL) has disclosed Intangibles for 5 consecutive years, with $20.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles changed N/A year-over-year to $20.3 million, compared with a TTM value of $20.3 million through Sep 2025, changed N/A, and an annual FY2024 reading of $12.4 million, changed N/A over the prior year.
  • Intangibles was $20.3 million for Q3 2025 at Autolus Therapeutics, up from $12.9 million in the prior quarter.
  • Across five years, Intangibles topped out at $20.3 million in Q3 2025 and bottomed at $65000.0 in Q4 2021.
  • Average Intangibles over 3 years is $11.6 million, with a median of $12.5 million recorded in 2025.